Lanzamiento Enero 2027

Reporte de caso2025Acceso abierto

Unmasking Potential Withdrawal Effects of Ashwagandha: A Case Report and Review

Holzman A, Brown AE, Kelley J, Rappaport D, Martini WA

Cureus · 0 citas

Cómo se estudió

Diseño
Reporte de caso (indexado por PubMed)
Estudiado en
Personas
Resultado principal
Marcadores de salud y funcionamiento

Quién lo pagó

Financiación
Financiación independiente

Según la declaración de financiación del texto completo.

Publicación

Publicado
2025-05-06 · Cureus · vol. 17 · número 5 · pág. e83577
Editorial
Cureus, Inc.
Citado
2 citas · más que el 87% de estudios similares · 2.3× el promedio de su campo
Referencias
22 trabajos
Acceso
Acceso abierto (publicación gratuita) · CC-BY
Áreas de investigación
Phytochemicals and Medicinal Plants · Complementary and Alternative Medicine Studies
Palabras clave
Medicine, Traditional medicine

5 autores

  • Andrew E. Holzman🇺🇸Mayo Clinic in Arizona; Mayo Clinic Hospital
  • Adam E Brown🇺🇸Mayo Clinic in Arizona; Mayo Clinic Hospital
  • J. L. Kelley🇺🇸University of Arizona
  • Douglas E. Rappaport🇺🇸Mayo Clinic Hospital
  • Wayne A Martini🇺🇸Mayo Clinic Hospital

Resumen

El texto original del estudio, en el idioma en que se publicó.

Ashwagandha (Withania somnifera) is a widely available herbal product often taken for stress-related concerns. While it is typically well-tolerated, individuals may occasionally experience side effects. Symptoms emerging after the discontinuation of ashwagandha have not been extensively documented. We report the case of a 20-year-old male who presented with tachycardia, insomnia, and symptoms of anxiety following abrupt discontinuation of ashwagandha extract (600 mg/day). His medical workup, including cardiac enzymes, electrocardiogram, complete blood count, liver function tests, and thyroid function tests, was unremarkable. His symptoms began shortly after cessation of ashwagandha, and no other clear medical or psychosocial stressors were identified. He was treated supportively with hydroxyzine for sleep and referred for outpatient psychiatric follow-up. This case may represent a withdrawal syndrome related to ashwagandha cessation, potentially mediated by its GABA-ergic activity. Although alternative explanations, such as recurrence of underlying anxiety, are possible, the timing and severity of symptoms after discontinuation suggest a withdrawal phenomenon. This case highlights the importance of assessing herbal supplement use in patients presenting with new-onset psychiatric or autonomic symptoms. Clinicians should be aware of the potential for withdrawal symptoms following ashwagandha cessation. A thorough history of supplement use should be included in the evaluation of patients presenting with anxiety, insomnia, or related complaints.

Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).

Confianza de la comunidad

Cargando…

¿Cuánto confías en los hallazgos de este estudio?

0 · nada10 · totalmente

Comentarios

¿Algo está mal aquí?

Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.

Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.